Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Top Cited Papers
- 25 February 2011
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 377 (9768), 813-822
- https://doi.org/10.1016/s0140-6736(10)62344-6
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Treatment and prevention of bone complications from prostate cancerBone, 2010
- Role of targeted therapy in the treatment of advanced prostate cancerBJU International, 2010
- Estimates of cancer incidence and mortality in Europe in 2008European Journal Of Cancer, 2010
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trialsThe Lancet Oncology, 2009
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 TrialEuropean Urology, 2009
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Histopathological Assessment of Prostate Cancer Bone Osteoblastic MetastasesJournal of Urology, 2008
- Osteoclast differentiation and activationNature, 2003